Alzamend Neuro (NASDAQ:ALZN) vs. Rhythm Pharmaceuticals (NASDAQ:RYTM) Critical Analysis

Alzamend Neuro (NASDAQ:ALZN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings and Valuation

This table compares Alzamend Neuro and Rhythm Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51 million	($2.16)	-0.56
Rhythm Pharmaceuticals	$217.17 million	32.00	-$196.54 million	($3.13)	-32.39

Alzamend Neuro has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Alzamend Neuro and Rhythm Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1	0	1	0	2.00
Rhythm Pharmaceuticals	1	2	14	1	2.83

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 2,195.08%. Rhythm Pharmaceuticals has a consensus target price of $133.13, suggesting a potential upside of 31.30%. Given Alzamend Neuro’s higher probable upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Rhythm Pharmaceuticals.

Insider & Institutional Ownership

49.6% of Alzamend Neuro shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Alzamend Neuro and Rhythm Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

About Alzamend Neuro

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.